Garcia-Cortes M, et al. Drug induced liver injury: an update. Arch Toxicol. 2020;94(10):3381–407.

Article  PubMed  CAS  Google Scholar 

Li X, Tang J, Mao Y. Incidence and risk factors of drug-induced liver injury. Liver Int. 2022;42(9):1999–2014.

Article  PubMed  Google Scholar 

Hassan A, Fontana RJ. The diagnosis and management of idiosyncratic drug-induced liver injury. Liver Int. 2019;39(1):31–41.

Article  PubMed  CAS  Google Scholar 

Moosa MS, et al. A randomized controlled trial of intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug-Induced Liver Injury. Clin Infect Dis. 2021;73(9):e3377–83.

Article  PubMed  CAS  Google Scholar 

Walker PA, et al. The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development. Arch Toxicol. 2020;94(8):2559–85.

Article  PubMed  PubMed Central  Google Scholar 

Babai S, Auclert L, Le-Louet H. Safety data and withdrawal of hepatotoxic drugs. Therapie. 2021;76(6):715–23.

Article  PubMed  Google Scholar 

Bjornsson HK, Bjornsson ES. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med. 2022;97:26–31.

Article  PubMed  CAS  Google Scholar 

Danan G, Teschke R. RUCAM in Drug and Herb Induced Liver Injury: the Update. Int J Mol Sci. 2015;17(1).

Turpeinen M, et al. Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: a comparative study in vitro. Xenobiotica. 2007;37(12):1367–77.

Article  PubMed  CAS  Google Scholar 

Gao W, et al. Interspecies differences in pharmacokinetics and metabolism of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethylphenyl)-propionamide: the role of N-acetyltransferase. Drug Metab Dispos. 2006;34(2):254–60.

Article  PubMed  CAS  Google Scholar 

Court MH, Greenblatt DJ. Molecular genetic basis for deficient acetaminophen glucuronidation by cats: UGT1A6 is a pseudogene, and evidence for reduced diversity of expressed hepatic UGT1A isoforms. Pharmacogenetics. 2000;10(4):355–69.

Article  PubMed  CAS  Google Scholar 

Court MH. Feline drug metabolism and disposition: pharmacokinetic evidence for species differences and molecular mechanisms. Vet Clin North Am Small Anim Pract. 2013;43(5):1039–54.

Article  PubMed  Google Scholar 

Antherieu S, et al. Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metab Dispos. 2010;38(3):516–25.

Article  PubMed  CAS  Google Scholar 

Andersson TB, Kanebratt KP, Kenna JG. The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human. Expert Opin Drug Metab Toxicol. 2012;8(7):909–20.

Article  PubMed  CAS  Google Scholar 

Ramos MJ, et al. In vitro models for non-alcoholic fatty liver disease: emerging platforms and their applications. iScience. 2022;25(1):103549.

Article  PubMed  Google Scholar 

Antherieu S, et al. Optimization of the HepaRG cell model for drug metabolism and toxicity studies. Toxicol Vitro. 2012;26(8):1278–85.

Article  CAS  Google Scholar 

Heintze T, et al. Effects of diminished NADPH:cytochrome P450 reductase in human hepatocytes on lipid and bile acid homeostasis. Front Pharmacol. 2021;12:769703.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Antoun J, et al. CYP4A11 is repressed by retinoic acid in human liver cells. FEBS Lett. 2006;580(14):3361–7.

Article  PubMed  CAS  Google Scholar 

Rogue A, et al. Interindividual variability in gene expression profiles in human hepatocytes and comparison with HepaRG cells. Drug Metab Dispos. 2012;40(1):151–8.

Article  PubMed  CAS  Google Scholar 

Szabo M, et al. Comparison of human hepatoma HepaRG cells with human and rat hepatocytes in uptake transport assays in order to predict a risk of drug induced hepatotoxicity. PLoS ONE. 2013;8(3):e59432.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Le Vee M, et al. Polarized expression of drug transporters in differentiated human hepatoma HepaRG cells. Toxicol Vitro. 2013;27(6):1979–86.

Article  Google Scholar 

Antherieu S, et al. Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells. Hepatology. 2011;53(6):1895–905.

Article  PubMed  CAS  Google Scholar 

Rodrigues RM, et al. Assessment of an automated in vitro basal cytotoxicity test system based on metabolically-competent cells. Toxicol Vitro. 2013;27(2):760–7.

Article  CAS  Google Scholar 

Verheijen M, et al. DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitro. Sci Rep. 2019;9(1):4641.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rose S, et al. DMSO-free highly differentiated HepaRG spheroids for chronic toxicity, liver functions and genotoxicity studies. Arch Toxicol. 2022;96(1):243–58.

Article  PubMed  CAS  Google Scholar 

Aritomi K, et al. Evaluation of three-dimensional cultured HepG2 cells in a nano culture plate system: an in vitro human model of acetaminophen hepatotoxicity. J Pharmacol Sci. 2014;124(2):218–29.

Article  PubMed  CAS  Google Scholar 

Bulutoglu B, et al. A comparison of hepato-cellular in vitro platforms to study CYP3A4 induction. PLoS ONE. 2020;15(2):e0229106.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Griffin SJ, Houston JB. Prediction of in vitro intrinsic clearance from hepatocytes: comparison of suspensions and monolayer cultures. Drug Metab Dispos. 2005;33(1):115–20.

Article  PubMed  CAS  Google Scholar 

Lin C, Ballinger KR, Khetani SR. The application of engineered liver tissues for novel drug discovery. Expert Opin Drug Discov. 2015;10(5):519–40.

Article  PubMed  CAS  Google Scholar 

Ware BR, et al. A Cell Culture platform to maintain long-term phenotype of primary human hepatocytes and endothelial cells. Cell Mol Gastroenterol Hepatol. 2018;5(3):187–207.

Article  PubMed  Google Scholar 

Sison-Young RL, et al. Comparative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the Capacity for Drug Disposition, Bioactivation, and Detoxication. Toxicol Sci. 2015;147(2):412–24.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Handin N, et al. Conditions for maintenance of hepatocyte differentiation and function in 3D cultures. iScience. 2021;24(11):103235.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bell CC, et al. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Sci Rep. 2016;6:25187.

Article  PubMed  PubMed Central